Macter International Ltd. · PSX:MACTER
Macter International — H1 FY2025-26 Earnings Presentation
21 slides from Macter International's earnings presentation, Mar 17, 2026
Slide 1: Letter to Pakistan Stock Exchange on Corporate Briefing Session
March 17, 2026 The General Manager Pakistan Stock Exchange Limited Stock Exchange Building, Stock Exchange Road, Karachi Subject: Presentation of Corporate Briefing Session Dear Sir, Please find attached herewith presentation with respect to the Corporate Briefing Session (CBS) of Macter Internation
Slide 2: Macter International Limited Corporate Briefing Session Half year FY 2025-26
Macter International Limited Corporate Briefing Session Half year FY 2025-26 1
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION IS NOT AN OFFER OR SOLICITATION OF AN OFFER TO BUY OR SELL ANY SECURITIES OR ANY INVESTMENT This presentation has been prepared by Macter International Limited (“Macter”) solely for information purposes. No representation or warranty express or implied is made thereto, a
Slide 4: Company Overview: Key Business Highlights
Company Overview Key Business Highlights Company Highlights Widespread Distribution Network ▪ History and Background: 'Macter International Limited (the Company) was incorporated in Pakistan in 1992 as a private limited Khyber Pakhtunkhwa company and was converted into a public limited company in 20
Slide 5: Company Overview: State of the art Facility and Focus on R&D
Company Overview State of the art Facility and Focus on Research and Development State-of-the-art cGMP compliant manufacturing facilities with an ability to manufacture difficult to make dosages. ▪ Manufacturing Facility: The high-tech plant produces a wide ▪ Macter’s Research and Development (R&D)
Slide 6: Manufacturing Facility Overview
Manufacturing Facility Overview ▪ The Biological facility has the capability of vials, pre-filled syringes and pen cartridges ▪ The facility has a capacity of over 55 million units (single shift) per annum compact line with Watson Marlow pumps, lyophilizer, inspection, labelling and packing line. ▪
Slide 7: Manufacturing Facility Overview
Manufacturing Facility Overview ▪ The Company has the manufacturing capability of producing Sterile Parental Products, MDI’s, DPI’s, Tablets, Capsules, Ointments, VVR, liquids, injections and dry suspensions ▪ Machinery is a combination of various leading international brands including Bosch, Bausch
Slide 8: Financial Highlights – Profit & Loss
Financial Highlights – Profit & Loss For the period ended December 31, 2025 December 31, December 31, Particulars Variance 2025 2024 Sales 6,110 4,920 24% Gross profit 2,943 2,202 34% Operating expenses 2,073 1,567 32% Other expenses 67 49 37% Other income 29 40 -28% Operating profit 832 625 33% Fin
Slide 9: Sales & Profit Performance
Financial Highlights Sales & Profit Performance Growth in sales and profit reflects sustained expansion of the local portfolio, strong traction from new product launches in low-competition and niche segments, and a continued increase in export volumes. 6,110 4,920 Net turnover for the period ended 3
Slide 10: Financial Highlights - Statement of Financial Position
Financial Highlights - Statement of Financial Position As at December 31, 2025 December June 30, December JUN 30, DESCRIPTION 31, 2025 2025 DESCRIPTION 31, 2025 2025 RUPEES IN MILLION RUPEES IN MILLION Property, plant and equipment 2,839 2,651 Issued, subscribed and paid-up capital 458 458 Capital r
Slide 11: Half year trend – PKR in Millions
Financial Highlights Half year trend – PKR in Millions SALES GROSS PROFIT 7,000 3,500 6,110 2,943 6,000 3,000 4,920 4,995 5,000 2,500 2,202 2,256 3,779 3,955 4,000 3,581 2,000 1,728 2,901 1,550 1,454 3,000 2,541 2,601 2,551 2,760 1,500 1,235 1,140 1,234 1,011 1,104 2,000 1,000 1,000 500 0 0 1H FY21
Slide 12: Key Ratios - Profitability Ratios
Financial Highlights Key Ratios - Profitability Ratios GROSS PROFIT (%) OPERATING PROFIT (%) 50 16 48 14 48 14 12 12 46 45 45 10 10 9 9 9 44 42 8 42 42 41 6 40 4 38 2 36 0 FY21 FY22 FY23 FY24 FY25 HY25-26 FY21 FY22 FY23 FY24 FY25 HY25-26 PROFIT BEFORE TAX (%) NET PROFIT (%) 14 8 7 13 7 12 11 7 6 6 6
Slide 13: Key Ratios - Profitability Ratios
Financial Highlights Key Ratios - Profitability Ratios EBITDA MARGIN (%) RETURN ON ASSET (%) 18 12 11 16 16 15 14 10 14 13 12 8 8 12 12 8 7 7 10 6 6 8 6 4 4 2 2 0 0 FY21 FY22 FY23 FY24 FY25 HY25-26 FY21 FY22 FY23 FY24 FY25 HY25-26 EFFECTIVE TAX RATE (%) RETURN ON EQUITY BEFORE TAX (%) 50 35 45 45 30
Slide 14: Key Ratios - Profitability Ratios
Financial Highlights Key Ratios - Profitability Ratios RETURN ON CAPITAL EMPLOYED (%) 30 26 25 21 20 19 17 18 16 15 10 5 0 FY21 FY22 FY23 FY24 FY25 HY25-26 RETURN ON EQUITY AFTER TAX (%) 25 19 19 20 15 14 13 12 10 10 5 0 FY21 FY22 FY23 FY24 FY25 HY25-26 13
Slide 15: Key Ratios - Liquidity Ratios
Financial Highlights Key Ratios - Liquidity Ratios CURRENT RATIO (TIMES) CASH FLOW TO CAPITAL 2.5 EXPENDITURES (TIMES) 3.5 2.0 1.9 1.9 2.9 1.8 3.0 1.7 1.8 2.6 2.5 1.5 1.2 2.0 1.8 1.7 1.0 1.5 1.3 1.0 0.8 0.5 0.5 0.0 0.0 FY21 FY22 FY23 FY24 FY25 HY25-26 FY21 FY22 FY23 FY24 FY25 HY25-26 CASH FLOW FROM
Slide 16: Key Ratios - Activity / Turnover Ratios
Financial Highlights Key Ratios - Activity / Turnover Ratios NO. OF DAYS IN INVENTORY NO. OF DAYS IN RECEIVABLES 180 50 164 45 157 45 160 151 139 142 40 140 122 35 120 30 28 100 25 22 80 19 19 20 60 15 15 40 10 20 5 0 0 FY21 FY22 FY23 FY24 FY25 HY25-26 FY21 FY22 FY23 FY24 FY25 HY25-26 NO. OF DAYS IN
Slide 17: Key Ratios Investment / Market Ratios
Financial Highlights Key Ratios Investment / Market Ratios EPS (RS.) P/E RATIO (TIMES) 18.0 35 16.1 31 16.0 30 14.0 25 25 12.0 20 10.0 9.3 9.3 20 17 8.6 8.0 7.2 6.6 15 11 6.0 10 10 4.0 5 2.0 0.0 0 FY21 FY22 FY23 FY24 FY25 HY25-26 FY21 FY22 FY23 FY24 FY25 HY25-26 Last three years Particulars P/E Rati
Slide 18: Key Ratios Investment / Market Ratios: DPS and Payout
Financial Highlights Key Ratios Investment / Market Ratios DPS (RS.) DIVIDEND PAYOUT (%) 4.50 4.24 70.0 64.6 4.00 3.80 60.0 3.50 3.32 50.0 46.2 3.00 2.50 2.25 40.0 2.00 30.0 24.1 23.6 1.50 1.08 20.0 1.00 12.6 10.0 0.50 0.00 0.0 FY21 FY22 FY23 FY24 FY25 FY21 FY22 FY23 FY24 FY25 17
Slide 19: New Product Launches GLP-1
New Product Launches GLP-1 Pakistan’s 1st r-DNA biological Semaglutide is now available in a complete range of Pre-filled syringe (PFS) and Pen. TirzaTrim is a dual Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) receptor agonist, indicated for the management o
Slide 20: New Product Launches - others
New Product Launches - others 19
Slide 21: Thank You Q & A Session
Macter Thank You Q & A Session 20
Macter International — H1 FY2025-26 Earnings Presentation on 6ix